|Bid||13.80 x 0|
|Ask||14.10 x 0|
|Day's Range||13.80 - 13.80|
|52 Week Range||4.96 - 13.80|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Amicus Therapeutics CEO John Crowley on how his fight to find a cure for his children's rare disease, Pompe, has driven his work in the pharmaceutical industry.
Why invest in a stock whose growth outlook that lags behind the market? Investors looking for companies with extraordinary future prospects in terms of profitability and returns should look atRead More...
Individual investors like stocks with a high growth potential. These companies have a strong outlook that can bring a significant upside to your portfolio, regardless of market cyclicality. Analysing theRead More...
Amicus Therapeutics Inc (NASDAQ:FOLD), a biotechnology company based in United States, saw a decent share price growth in the teens level on the NasdaqGM over the last few months. WithRead More...
On a per-share basis, the Cranbury, New Jersey-based company said it had a loss of 69 cents. Losses, adjusted for one-time gains and costs, came to 41 cents per share. The results missed Wall Street expectations. ...
Amicus Therapeutics, Inc. (FOLD) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Sarepta Therapeutics and Amicus Therapeutics are tackling the unmet need for new treatments for rare conditions, and that could put them in position to generate market-beating returns.
Biotech stocks narrowed in on a 21-month high Wednesday with big rises coming from the likes of Intercept, Amicus and Exelixis on positive drug and partnership news.
Shares of Amicus Therapeutics, Inc. (NASDAQ: FOLD ) were trading higher by more than 12 percent Wednesday after the company released encouraging clinical trial data. The company's therapy showed a greater ...
Amicus Therapeutics Inc said on Wednesday it would stop developing its experimental drug for healing wounds related to a rare skin disease, but shares of the company rose as investors appeared to focus on the drug developer's expanding pipeline. Amicus's shares rose as much as 6 percent in morning trading, recovering from a nearly 15 percent slide before the bell.
U.S. drug developer Amicus Therapeutics Inc said on Wednesday its drug to treat wounds failed to meet the main goals of a late-stage clinical trial. The company said its drug, when compared with a placebo, ...
Amicus Therapeutics (FOLD) needs Investors to pay close attention to the stock based on moves in the options market lately.
Amicus' stock continues to benefit from its emerging rare disease pipeline and the industrywide upswing in biotech valuations this year.
The Food and Drug Administration changed its tune on Amicus' lead drug, and shareholders couldn't be happier.